CD137/FAP agonist
CD137/FAP agonist
Search
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
KRAS multi-inhibitor
KRAS multi-inhibitor
NPY2r agonist
Food intake regulator
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Survodutide (BI 456906)
Survodutide (BI 456906)
BI 765845
Heart disease modulator
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Pets
Pets
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Retinal Health: Meet the Scientists
We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Survodutide (BI 456906)
BI 456909
Ruminants
Ruminants
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Fencovis®
Indicated for infectious diseases in cattle
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients